Search research articles
Contact Us
Filters
Showing results (21-30 of 240) with videos related to
Page
of 24
Sort By:
The New England Journal of Medicine
|
January 21, 2026
European Study of Prostate Cancer Screening - 23-Year Follow-up
Derek Raghavan, Ian F Tannock
JCO Oncology Practice
|
October 13, 2025
Conflict of Interest: Moving From Disclosure to Avoidance
Ian F Tannock, Saroj Niraula
Journal of the National Cancer Institute
|
January 2, 2003
Placebo effects in oncology
Gisèle Chvetzoff, Ian F Tannock
Nature Reviews. Clinical Oncology
|
September 3, 2025
Non-financial conflicts of interest
Saroj Niraula, Ian F Tannock
Nature Clinical Practice. Oncology
|
July 17, 2008
Intermittent androgen blockade should be regarded as standard therapy in prostate cancer
Bostjan Seruga, Ian F Tannock
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 14, 2009
Up-front use of aromatase inhibitors as adjuvant therapy for breast cancer: the emperor has no clothes
Bostjan Seruga, Ian F Tannock
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 22, 2005
Effect of the selective estrogen receptor modulator arzoxifene on repopulation of hormone-responsive breast cancer xenografts between courses of chemotherapy
Licun Wu, Ian F Tannock
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 14, 2003
Selective estrogen receptor modulators as inhibitors of repopulation of human breast cancer cell lines after chemotherapy
Wu Licun, Ian F Tannock
Nature Reviews. Clinical Oncology
|
February 6, 2013
Breast cancer: Tamoxifen--when more might be better
Carlos Caldas, Ian F Tannock
Nature Reviews. Urology
|
December 4, 2009
Prostate cancer: Androgen deprivation therapy and bone loss
Eitan Amir, Ian F Tannock
Page
of 24
Search research articles
Search
Showing results (21-30 of 240) with videos related to
Sort By:
Page
of 24
The New England Journal of Medicine
|
January 21, 2026
European Study of Prostate Cancer Screening - 23-Year Follow-up
Derek Raghavan, Ian F Tannock
JCO Oncology Practice
|
October 13, 2025
Conflict of Interest: Moving From Disclosure to Avoidance
Ian F Tannock, Saroj Niraula
Journal of the National Cancer Institute
|
January 2, 2003
Placebo effects in oncology
Gisèle Chvetzoff, Ian F Tannock
Nature Reviews. Clinical Oncology
|
September 3, 2025
Non-financial conflicts of interest
Saroj Niraula, Ian F Tannock
Nature Clinical Practice. Oncology
|
July 17, 2008
Intermittent androgen blockade should be regarded as standard therapy in prostate cancer
Bostjan Seruga, Ian F Tannock
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 14, 2009
Up-front use of aromatase inhibitors as adjuvant therapy for breast cancer: the emperor has no clothes
Bostjan Seruga, Ian F Tannock
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 22, 2005
Effect of the selective estrogen receptor modulator arzoxifene on repopulation of hormone-responsive breast cancer xenografts between courses of chemotherapy
Licun Wu, Ian F Tannock
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 14, 2003
Selective estrogen receptor modulators as inhibitors of repopulation of human breast cancer cell lines after chemotherapy
Wu Licun, Ian F Tannock
Nature Reviews. Clinical Oncology
|
February 6, 2013
Breast cancer: Tamoxifen--when more might be better
Carlos Caldas, Ian F Tannock
Nature Reviews. Urology
|
December 4, 2009
Prostate cancer: Androgen deprivation therapy and bone loss
Eitan Amir, Ian F Tannock
Page
of 24